Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis

• Published in: Frontiers in immunology Vol. 11; p. 594
• Main Authors: Haschka, David, Tymoszuk, Piotr, Bsteh, Gabriel, Petzer, Verena, Berek, Klaus, Theurl, Igor, Berger, Thomas, Weiss, Günter
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.04.2020
• Subjects: Adult; Aged; Biomarkers - blood; classical monocytes; Female; Flow Cytometry - methods; Humans; Immunologic Factors - therapeutic use; Immunology; Immunophenotyping - methods; Male; Middle Aged; Monocytes - drug effects; Monocytes - immunology; multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - diagnosis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - immunology; Natalizumab - therapeutic use; neutrophils; Neutrophils - drug effects; Neutrophils - immunology; nonclassical monocytes; relapsing-remitting multiple sclerosis; nonclassical monocytes; neutrophils; multiple sclerosis; classical monocytes; relapsing-remitting multiple sclerosis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.00594

Neutrophils and monocytes encompassing the classical, intermediate, and nonclassical population constitute the majority of circulating myeloid cells in humans and represent the first line of innate immune defense. As such, changes in their relative and absolute amounts serve as sensitive markers of diverse inflammatory conditions. Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, causing demyelination and axonal loss, affecting various neuron functions and often causing irreversible neurological disability. MS disease course is individually highly heterogeneous but can be classified as progressive (PMS) or relapsing-remitting (RRMS). Each MS course type may be further characterized as active or inactive, depending on the recent disability progression and/or current relapses. Data on specific alterations of the myeloid compartment in association with MS disease course are scarce and conflicting. In the current study, we systematically immunophenotyped blood myeloid leukocytes by flow cytometry in 15 healthy and 65 MS subjects. We found a highly significant expansion of granulocytes, CD15 neutrophils, and classical and nonclassical monocytes in inactive RRMS (RRMSi) with concomitant shrinkage of the lymphocyte compartment, which did not correlate with biochemical readouts of systemic inflammation. Each of these leukocyte populations and the combined myeloid signature accurately differentiated RRMSi from other MS forms. Additionally, nonclassical monocyte proportions were particularly elevated in RRMSi individuals receiving disease-modifying therapy (DMT), such as natalizumab. Our results suggest that flow cytometry-based myeloid cell immunophenotyping in MS may help to identify RRMSi earlier and facilitate monitoring of DMT response.